{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:19:25Z","timestamp":1770743965661,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urolonc.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:50:13Z","timestamp":1722973813000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0233-0607","authenticated-orcid":false,"given":"David E.","family":"Hinojosa-Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal","family":"Saffati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Salgado-Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Kronstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aihua E.","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy R.","family":"Slawin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.urolonc.2024.07.006_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2024.07.006_bib0002","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0003","first-page":"50","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0004","unstructured":"Cancer of the Urinary Bladder - Cancer Stat Facts. SEER. Accessed: March 19, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"issue":"2","key":"10.1016\/j.urolonc.2024.07.006_bib0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive\/advanced cancer of the urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.07.006_bib0006","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.07.006_bib0007","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2024.07.006_bib0008","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.urolonc.2024.07.006_bib0009","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jamaoncol.2019.0182","article-title":"Treatment of metastatic urothelial cancer in 2018","volume":"5","author":"Bellmunt","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.07.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.urolonc.2024.07.006_bib0011","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2024.07.006_bib0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.07.006_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.07.006_bib0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmjebm-2022-111928","article-title":"Theory and practice of Bayesian and frequentist frameworks for network meta-analysis","volume":"28","author":"Sadeghirad","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"10236","key":"10.1016\/j.urolonc.2024.07.006_bib0016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"13","key":"10.1016\/j.urolonc.2024.07.006_bib0017","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2024.07.006_bib0018","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2024.07.006_bib0019","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2024.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"Van Der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2024.07.006_bib0021","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.urolonc.2024.07.006_bib0022","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccines Immunother."},{"key":"10.1016\/j.urolonc.2024.07.006_bib0023","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0024","first-page":"1","article-title":"Predicting bladder cancer responses to PD-L1 inhibitors? A case report and overview for the busy clinician","volume":"5","author":"N","year":"2020","journal-title":"J Transl Sci"},{"issue":"11","key":"10.1016\/j.urolonc.2024.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.07.006_bib0026","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2217\/imt-2015-0002","article-title":"The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis","volume":"8","author":"Aguiar","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.ai.2015.12.003","article-title":"Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy","volume":"130","author":"Spranger","year":"2016","journal-title":"Adv Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0028","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0030","unstructured":"National Comprehensive Cancer Network. Bladder Cancer. Published online: May 9, 2024. Accessed: June 14, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"issue":"25","key":"10.1016\/j.urolonc.2024.07.006_bib0031","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0032","unstructured":"U.S. Food and Drug Administration C for DE and R. FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma. FDA. Published online: April 3, 2023. Accessed: March 19, 2024.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic."},{"issue":"3","key":"10.1016\/j.urolonc.2024.07.006_bib0033","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0034","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2147\/JMDH.S410301","article-title":"Machine learning and AI in cancer prognosis, prediction, and treatment selection: a critical approach","volume":"16","author":"Zhang","year":"2023","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0035","doi-asserted-by":"crossref","first-page":"16444","DOI":"10.1038\/s41598-018-34753-5","article-title":"Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy","volume":"8","author":"Huang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.07.006_bib0036","article-title":"Applications of circulating tumor DNA in immune checkpoint inhibition: emerging roles and future perspectives","volume":"12","author":"Lu","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0037","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41698-023-00417-5","article-title":"Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR\/HDAC targeted therapy","volume":"7","author":"Wang","year":"2023","journal-title":"Npj Precis Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2024.07.006_bib0039","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.07.006_bib0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-019-0730-9","article-title":"Combination regimens with PD-1\/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:49:45Z","timestamp":1725360585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1078143924005441"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}